Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA

por Schjesvold, Fredrik H, Bakker, Nicolaas A, Sonneveld, Pieter
Publicado 2022

Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma

por Kaufman, Jonathan L., Gasparetto, Cristina, Schjesvold, Fredrik H., Moreau, Philippe, Touzeau, Cyrille, Facon, Thierry, Boise, Lawrence H., Jiang, Yanwen, Yang, Xiaoqing, Dunbar, Fengjiao, Vishwamitra, Deeksha, Unger, Stefanie, Macartney, Tammy, Pesko, John, Yu, Yao, Salem, Ahmed Hamed, Ross, Jeremy A., Hong, Wan‐Jen, Maciag, Paulo C., Pauff, James M., Kumar, Shaji
Publicado 2021

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of H...

por Groen, Kazimierz, Schjesvold, Fredrik H., van der Holt, Bronno, Levin, Mark-David, Seefat, Maarten R., Hansson, Markus, Leys, Maria B.L., Regelink, Josien C., Waage, Anders, Szatkowski, Damian, Axelsson, Per, Hieu Do, Trung, Svirskaite, Asta, van der Spek, Ellen, Haukas, Einar, Knut-Bojanowska, Dorota, Ypma, Paula F., Blimark, Cecilie H., Mellqvist, Ulf-Henrik, van de Donk, Niels W.C.J., Sonneveld, Pieter, Klostergaard, Anja, Vangsted, Annette J., Abildgaard, Niels, Zweegman, Sonja
Publicado 2023

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

por Schmitz, Alexander, Brøndum, Rasmus Froberg, Johnsen, Hans Erik, Mellqvist, Ulf-Henrik, Waage, Anders, Gimsing, Peter, op Bruinink, Davine Hofste, van der Velden, Vincent, van der Holt, Bronno, Hansson, Markus, Andersen, Niels Frost, Frølund, Ulf Christian, Helleberg, Carsten, Schjesvold, Fredrik H., Ahlberg, Lucia, Gulbrandsen, Nina, Andreasson, Bjorn, Lauri, Birgitta, Haukas, Einar, Bødker, Julie Støve, Roug, Anne Stidsholt, Bøgsted, Martin, Severinsen, Marianne T., Gregersen, Henrik, Abildgaard, Niels, Sonneveld, Pieter, Dybkær, Karen
Publicado 2022

Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autolog...

por Zweegman, Sonja, Stege, Claudia A.M., Haukas, Einar, Schjesvold, Fredrik H., Levin, Mark-David, Waage, Anders, Leys, Rineke B.L., Klein, Saskia K., Szatkowski, Damian, Axelsson, Per, Do, Trung Hieu, Knut-Bojanowska, Dorota, van der Spek, Ellen, Svirskaite, Asta, Klostergaard, Anja, Salomo, Morten, Blimark, Celine, Ypma, Paula F., Mellqvist, Ulf-Hendrik, Poddighe, Pino J., Stevens-Kroef, Marian, van de Donk, Niels W.C.J., Sonneveld, Pieter, Hansson, Markus, van der Holt, Bronno, Abildgaard, Niels
Publicado 2020